

7. Literatur

1. Hufnagel CA. Aortic plastic valvular prostheses.
Bull Georgetown U Med Cent 1951;4:128-130.
2. Cohn LH, Allred EN, DiSesa VJ, Sawtelle K, Shemin RJ, Collins JJ Jr. Early and late risk of aortic valve replacement. A 12 year concomitant comparison of porcine bioprosthetic and tilting disc prosthetic aortic valves.
J Thorac Cardiovasc Surg 1984;88:695-705.
3. Hume M, Chan YK. Examination of the blood in the presence of venous thrombosis.
JAMA 1967;200:747-750.
4. Casselman FP, Bots ML, Van Lommel W, Knaepen PJ, Lensen R, Vermeulen FEE. Repeated thromboembolic and bleeding events after mechanical aortic valve replacement.
Ann Thorac Surg 2001;71:1172-1180.
5. Murray G. Homologous aortic valve segment transplants as surgical treatment for aortic and mitral insufficiency.
Angiology 1956;7:46-50.
6. Bentall HH, De Bono A. A technique for complete replacement of the ascending aorta.
Thorax 1968;23:338-9.
7. Ross DN. Homograft replacement of the aortic valve.
Lancet 1962;2:487.
8. Barratt-Boyes BG. Homograft valve replacement for aortic valve disease.
Thorax 1965;20:495-504.
9. Shaddy RE, Hawkins JA. Immunology and failure of valves allografts in children.
Ann Thorac Surg 2002;74:1271-5.
10. Chambers JC, Somerville J, Stone S, Ross DN. Pulmonary autograft procedure for aortic valve disease.
Circulation 1997;96:2206-2214.
11. Buch WS, Angell WW, Shumway NE. Deterioration of formalin-treated aortic valve heterografts.
J Thorac Cardiovasc Surg 1970;60:673-82.
12. Ionescu MI, Smith DR, Sutherland TW. Heart valve replacement with aortic heterografts: follow up study.
Ann Thorac Surg 1972;13:1-14.

13. Rose AG. Pathology of the formalin-treated heterograft porcine aortic valve in the mitral position.
Thorax 1972;27:401-9.
14. Carpentier A, Lemaigre G, Robert L, Carpentier S, Dubost C. Biological factors affecting long-term results of valvular heterografts.
J Thorac Cardiovasc Surg 1969;58:467-83.
15. Carpentier A, Deloche A, Relland J, Fabiani JN, Forman J, Camilleri JP, Soyer R, Dubost C. Six year follow up of glutaraldehyde-preserved heterografts. With particular reference to the treatment of congenital valve malformations.
J Thorac Cardiovasc Surg 1974;68:771-82.
16. Kaiser GA, Hancock WD, Lukban SB, Litwak RS. Clinical use of a new design stented xenograft heart valve prosthesis.
Surg Forum 1969;20:137-8.
17. Horowitz MS, Goodman DJ, Fogarty TJ, Harrison DC. Mitral valve replacement with the glutaraldehyde-preserved porcine heterograft. Clinical, hemodynamic and pathological correlations.
J Thorac Cardiovasc Surg 1974;67:885-95.
18. Rothkopf M, Davidson T, Lipscomb K, Narahara K, Hillis LD, Willerson JT, Estrera A, Platt M, Mills L. Hemodynamic evaluation of the Carpentier-Edwards bioprosthesis in the aortic position.
Am J Cardiol 1979;44:209-14.
19. Davila JC, Magilligan DJ, Lewis JW, Jara FM, Lee MW, Alam M, Riddle JM, Stein PD. Spontaneous degeneration of porcine bioprosthetic valves.
Ann Thorac Surg 1980;30:259-66.
20. Oyer PE, Miller DC, Stinson EB, Ritz BA, Moreno-Cabral RJ, Shumway NE. Clinical durability of the Hancock porcine bioprosthetic valve.
J Thorac Cardiovasc Surg 1980;80:824-33.
21. Camillieri JP, Pornin B, Carpentier A. Structural changes of glutaraldehyde-treated porcine bioprosthetic valves.
Arch Pathol Lab Med 1982;106:490-6.
22. Kutsche LM, Oyer P, Shumway N, Baum D. An important complication of Hancock mitral valve replacement in children.
Circulation 1979;60(Suppl): I 98-I 103.

23. Geha AS, Hillel L, Stansel HC, Cornhill JF, Kilman JW, Buckley MJ, Roberts WC. Late failure of porcine valve heterografts in children. *J Thorac Cardiovasc Surg* 1979;78:351-64.
24. Sanders SP, Levy RJ, Freed MD; Norwood WI, Castaneda AR. Use of Hancock porcine xenografts in children and adolescents. *Am J Cardiol* 1980;46:429-38.
25. Cohn LH, Koster JK, Mee RB, Collins JJ. Long-term follow-up of the Hancock bioprosthetic heart valve. A 6 year review. *Circulation* 1979; 60(Suppl): I 87-I 92.
26. Ionescu MI, Tandon AP, Mary DA, Abid A. Heart valve replacement with the Ionescu-Shiley pericardial xenograft. *J Thorac Cardiovasc Surg* 1977;73:31-42.
27. Ionescu MI. The Ionescu-Shiley pericardial xenograft heart valve. In: Ionescu MI, Tandon AP, editors. *Tissue heart valves*. London: Butterworths, 1978;p201-210.
28. Tandon AP, Smith DR, Mary DA, Ionescu MI. Sequential hemodynamic studies in patients having aortic valve replacement with the Ionescu-Shiley pericardial xenograft. *Ann Thorac Surg* 1977;24:149-55.
29. Tandon AP, Smith DR, Whitaker W, Ionescu MI. Long-term hemodynamic evaluation of aortic pericardial xenograft. *Br Heart J* 1978;40:602-7.
30. Radio SJ, Suvalsky SD, Hofschire PJ, Fleming WH, Rogler WC, McManus BM. Rapid calcification of bovine pericardial valve in adolescence. *Arch Pathol Lab Med* 1985;109:1118-21.
31. Reul GJ, Cooley DA, Ducan JM, Frazier HO, Hallmann GL, Livesay JJ, Ott DA, Walker WE. Valve failure with the Ionescu-Shiley bovine pericardial bioprosthetic analysis of 2680 patients. *J Vasc Surg* 1985;2:192-204.
32. Galioto FMJ, Midgeley FM, Kapur S, Perry LW, Watson DC, Shapiro SR, Ruckman RN, Scott LP. Early failure of Ionescu-Shiley bioprosthesis after mitral valve replacement in children. *J Thorac Cardiovasc Surg* 1982;83:306-10.
33. Bailly P, Sauer P, Vouhe P. Experience 4 surgical centers with the Hancock pericardial valve. In: Bodnar E, Yacoub M, editors. *Biologic bioprosthetic valves*. New York: Yorke Medical books, 1998:723-735.

34. Gott JP, Chih P, Dorsey L, Jay JL, Jett GK, Schoen FJ, Girardot JM, Guyton RA. Calcification of porcine valves: a successful new method of antimineralization. *Ann Thorac Surg* 1992;53:207-216.
35. Jones M, Eidbo EE, Hilbert SL, Ferrans VJ, Clarck RE. Anticalcification treatments of bioprosthetic heart valves: in vivo studies in sheep. *J Cardiovasc Surg* 1989;4:69-73.
36. Grabenwöger M, Sider J, Fitzal F, Zelenka C, Windberger U, Grimm M. Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material. *Ann Thorac Surg* 1996;62:772-7.
37. Webb CL, Benedict JJ, Schoen FJ, Linden JA, Levy RJ. Inhibition of bioprosthetic valve calcification with aminodiphosphonate covalently bound material to residual aldehyde groups. *Ann Thorac Surg* 1988;46:309-16.
38. Vyavahare N, Hirsch D, Lerner E, Baskin J, Schoen FJ, Bianco R. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. *Circulation* 1997;95:479-88.
39. Schoen FJ, Harasaki H, Kim K, Anderson HC, Levy RJ. Biomaterial associated calcification: pathology, mechanisms, and strategies for prevention. *J Biomed Mater Res* 1988;22:11-36.
40. Schoen FJ, Levy RJ, Nelson AC, Bernard WF, Nashef A, Hawley M. Onset and progression of experimental bioprosthetic heart valve calcification. *Lab Invest* 1985;52:523-32.
41. O'Brien MF, Goldstein S, Walsh S, Black KS, Elkins R, Clarke D. The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization: first experimental studies before clinical implantation. *Semin Thorac Cardiovasc Surg* 1999;11(Suppl):I 194-I 200.
42. Leyh RG, Wilhelmi M, Rebe P, Fischer S, Kofidis T, Haverich A, Mertsching H. In vivo repopulation of xenogeneic and allogeneic acellular valve matrix conduits in the pulmonary circulation. *Ann Thorac Surg* 2003;75:1457-1463.
43. Rieder E, Kasimir MT, Silberhumer G, Seebacher G, Wolner E, Simon P, Weigel G. Decellularization protocols of porcine heart valves differ importantly in efficiency of

cell removal and susceptibility of the matrix to recellularization with human vascular cells.

J Thorac Cardiovasc Surg 2004;127:399-405.

44. Rashid ST, Salacinski HJ, Hamilton G, Seifalian AM. The use of animal models in developing the discipline of cardiovascular tissue engineering: a review. *Biomaterials* 2004;25:1627-1637.
45. Shinoka T, Breuer CK, Tanel RE, Zund G, Miura T, Ma PX, Langer R, Vacanti JP, Mayer JE Jr. Tissue engineering heart valves: valve leaflet replacement study in a lamb model. *Ann Thorac Surg* 1995;60:S513-S516.
46. Shinoka T, Ma PX, Shum-Tim D, Breuer CK, Cusick RA, Zund G, Langer R, Vacanti JP, Mayer JE Jr. Tissue engineering heart valves. Autologous valve leaflet replacement study in a lamb model. *Circulation* 1996;94(Suppl):III 64-III 68.
47. Hoerstrup SP, Sodian R, Daebritz S, Wang J, Bacha EA, Martin DP, Moran AM, Guleserian KJ, Sperling JS, Kaushal S, Vacant JP, Schoen FJ, Mayer JE Jr. Functional living trileaflet heart valves grown in vitro. *Circulation* 2000;107(Suppl):III 44-III 49.
48. Robicsek F. Leonardi da Vinci and the sinuses of Valsalva. *Ann Thorac Surg* 1991;52:328-335.
49. Bader A, Schilling T, Teebken OE, Brandes G, Herden T, Steinhoff G, Haverich A. Tissue engineering of heart valves; human endothelial cell seeding of detergent acellularized porcine valves. *Eur J Cardiothorac Surg* 1998;14:279-284.
50. Wilhelmi MH, Rebe P, Leyh R, Wilhelmi M, Haverich A, Mertsching H. Role of inflammation and ischemia after implantation of xenogeneic pulmonary valve conduits: histological evaluation after 6 and 12 months in sheep. *Int J Artif Organs* 2003;26:411-420.
51. Leyh R, Wilhelmi M, Haverich A, Mertsching H. A xenogeneic acellularized matrix for heart valve tissue engineering: in vivo study in a sheep model. *Z Kardiol* 2003;92:938-946.
52. Sievers HH, Stierle U, Schmidtke C, Bechtel M. Decellularized pulmonary homograft (SynerGraft) for reconstruction of the right ventricular outflow tract: first clinical experience.

- Z Kardiol 2003;92:53-59.
53. Bechtel JF, Muller-Steinhardt M, Schmidtke C, Brunswik A, Stierle U, Sievers HH. Evaluation of the decellularized pulmonary valve homograft (SynerGraft). *J Heart Valve Dis* 2003;12:734-739.
54. Kurihara T, Miyagawa S, Tomonaga K, Hazama K, Yamada J, Shirakura R, Matsuura Y. Sensitivity to human serum of gammaretroviruses produced from pig endothelial cells transduced with glycosyltransferase genes. *Xenotransplantation* 2003;10:562-568.
55. Magre S, Takeuchi Y, Bartosch B. Xenotransplantation and pig endogenous retroviruses. *Rev Med Virol* 2003;13:311-329.
56. Dohmen PM, Ozaki S, Yperman J, Flameng W, Konertz W. Results of Tissue engineered auto-xenograft implanted in the juvenile sheep model. *Med Sci Monit* 2003;9:BR97-BR107.
57. Elkins RC, Goldstein S, Hewitt CW, Walsh SP, Dawson PE, Ollerens JD, Black KS, Clarke DR, O'Brien MF. Recellularization of heart valve grafts by a process of adaptive remodeling. *Semin Thorac Cardiovasc Surg* 2001;13(Suppl):I 87-I 92.
58. Zund G, Hoerstrup SP, Schoeberlein A, Lachat M, Uhlschmid G, Vogt PR, Turina M. Tissue engineering: a new approach in cardiovascular surgery: Seeding of human fibroblasts followed by human endothelial cells on resorable mesh. *Eur J Cardiothorac Surg* 1998;13:160164.
59. Rashid ST, Salacinski HJ, Hamilton G, Seifalian AM. The use of animal models in developing the discipline of cardiovascular tissue engineering: a review. *Biomaterials* 2004;25:1627-1637.
60. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. *J Thromb Haemost* 2004;2:561-573.
61. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. *Science* 1999;284:1318-1322.
62. Sabik JF, Lytle BW, Blackstone EH, Marullo GM, Pettersson GB, Cosgrove DM. Aortic root replacement with cryopreserved allograft for prosthetic valve endocarditis. *Ann Thorac Surg* 2002;74:650-659.

63. Aranki SF, Santini F, Adams DH, Rizzo RJ, Couper GS, Kinchla NM, Gildea JS, Collins JJ Jr, Cohn LH. Aortic valve endocarditis. Determinants of early survival and late morbidity.
Circulation 1994;90:III 75-III 82.
64. Wilson WR, Danielson GK, Giuliani ER, Geraci JE. Prosthetic valve endocarditis.
Mayo Clin Proc 1982;57:155-161.
65. Bohm JO, Botha CA, Hemmer W, Roser D, Starck C, Blumenstock G, Rein JG. The Ross operation as a combined procedure and in complicated cases; is there an increased risk ?
Thorac Cardiovasc Surg 2001;49:300-305.
66. Zilla P, von Oppell U, Deutsch M. The endothelium: a key to the future.
J Card Surg 1993;8:32-60.
67. Dohmen PM, Ozaki S, Verbeken E, Yperman J, Flameng W, Konertz W. Tissue engineering of a pulmonary xenograft heart valve.
Asian Cardiovasc Thoracic Surg 2002; 10:25-30.
68. Ozaki S, Dohmen PM, Flameng W, Konertz W. Superiority of tissue engineered heart valves to stentless porcine aortic bioprostheses.
Artif Organ 2001;25: 846.
69. Welters Mj, Oei FB, Witvliet MD, Vaessen LM, Cromme-Dijkhuis AH, Bogers AJ, Weimar W, Claas FH. A broad and strong humoral immune response to donor HLA after implantation of cryopreserved human heart valve allografts.
Hum Immunol 2002;63:1019-1025.
70. Dor FJ, Oei FB, Vaessen LM, Marquet RL, Bogers AJ, Weimar W. Frequencies of donor-reactive helper T lymphocytes correlate with rejection of aortic valve allografts in rats.
J Heart Valve Dis 2002;11:326-334.
71. Mitchell RN, Jonas RA, Schoen FJ. Pathology of explanted cryopreserved allograft heart valves: comparison with aortic valves from orthotopic heart transplantation.
J Thorac Cardiovasc Surg 1998;115:118-127.
72. Moidl R, Simon P, Kupilik N, Chevchik O, Heinrich N, Moritz A, Wolner E, Laufer G. Increased pulmonary flow velocities in oversized homografts in patients after Ross procedure.
Eur J Cardiothorac Surg 1997;12:569-73.

73. Carr-White GS, Kilner PJ, Hon JK, Rutledge T, Edwards S, Burman ED, Pennell DJ, Yacoub MH. Incidence, location, pathology, and significance of pulmonary homograft stenosis after Ross operation.
Circulation 2001;104(Suppl): I 8-I 16.
74. Dohmen PM, Braun J, Konertz W. Early postoperative Difference between tissue engineered allografts and regular allografts.
Circulation 2001;104 (Suppl): II 761.
75. Dohmen PM, Lembcke A, Dushe S, Kivelitz D, Hotz H, Konertz W. Early clinical results of right ventricular outflow tract reconstruction with a tissue engineered pulmonary valve; in 23 consecutive patients.
Circulation 2003;108 (Suppl): II 621.